Oncoinvent ASA (0RU5) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

I'm Øystein Saug, I'm the CEO of the company and with me today I have Kari Myhren, the Chief Medical Officer. And since this is not a half-yearly report and merely a quarterly update, we will just give you an update of the developments of the company without the full financials. You can ask questions through the system and towards the end of the session we will strive to answer your questions. These are the disclaimers. Today we'll go through the highlights, also the upcoming milestones, and last but not least, give a clinical update with the latest data from our trials. So the biggest highlight of the quarter was certainly the final data in ovarian cancer, our phase one trial that read out in October. Kari will give you a detailed overview of those data in a few minutes. But also on the colorectal cancer side, we actually announced the data before the summer. But now, just last week, we presented the data on PSOGI, the International Congress for Peritoneal Surface Malignancies in Barcelona. On the corporate side, during the quarter we completed our merger, or reverse merger if you like, with Bergen Bio, thereby also uplisting from Your Next Growth to Oslo Börs main market. And we also have announced and secured a fully underwritten rights issue to be executed in November. And first let's talk about the merger with Bergen Bio. So the deal was signed in June and it was completed last week on the 29th of October. The merged company has taken the name Oncoinvent ASA, so the same as the old Oncoinvent, and is now trading on the Oslo main board under the old ticker Onkin. Now, for US shareholders, this does not require any particular action, but the Bergen Bio shareholders, they will now see their shares listed under a new name and under a new ticker. Now, following the m...